Blue Note Therapeutics Receives Breakthrough Device Designation from FDA for Prescription Digital Therapeutic to Treat Cancer-Related Anxiety and Depression
June 2020
Blue Note Therapeutics, Inc. announced that the U.S. FDA has granted Breakthrough Device Designation to BNT001, the company’s lead prescription digital therapeutic (PDT) candidate.
Read more →